GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE A RATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS
Silvana Lobo 1
Rita Monteiro 1
Liliana Sousa 1
Hugo Pinheiro 1
Sergio Castedo 1
Fatima Carneiro 2
Luzia Garrido 3
Manuel Teixeira 4
Genevieve Michils 5
Vicent Bours 6
Robin de Putter 7
Lisa Golmard 8
Chrystelle Colas 8
Maud Blanluet 8
Camille Desseignés 9
Coulet Florence 9
Stefan Aretz 10
Isabel Spier 11
Robert Hüneburg 11
Guglielmina Ranzani 12
Maurizio Genuardi 13
Ana Patiño-García 14
Conxi Lázaro 15
Gabriel Capellà 15
Joan Brunet-Vidal 16
Judith Balmana 17
Elena Domínguez-Garrido 18
Marjolin Ligtenberg 19
Rebecca FitzGerald 20
Emma Woodward 21
Gareth Evans 22
Helen Hanson 23
Conceição Egas 24
M. Isabel Tejada et al. 25
Nicoline Hoogerbrugge 25
Marc Tischkowitz 26
Carla Oliveira 27
José García Peláez 27
Patrick R. Benusiglio 27
Laura Gieldon & Evelyn Schrock 28
Elke Holinski-Feder & Verena Steinke 29
Daniele Calistri & Gianluca Tedaldi 30
Catarina Silveira & Inês Silva 31
Mateja Krajc, Ana Blatnik & Srdjan Novacovik 32
Jose Soto 33
Kristina Lagerstedt-Robinson & Svetlana Bajali Lagercrantz 34
Karim Dahan & Damien Feret 35
1 i3s, Porto, Portugal
2 IPATIMUP, Porto/PT, Porto, Portugal
3 Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal
4 IPO, Instituto Português de Oncologia do Porto, Porto, Portugal
5 University of Leuven, Leuven, Belgium
6 Laboratory of Human Genetics, GIGA-Institute, Liège, Belgium
7 University Hospital of Ghent, Ghent, Belgium
8 Institut Curie, Paris, France
9 GH Pitié- Salpêtrière, Paris, France
10 University Hospital Bonn, Bonn, Germany
11 University of Bonn, Bonn, Germany
12 University of Pavia, Pavia, Italy
13 Institute of Genomic Medicine, Catholic University of the Sacred Heart, Rome, Italy
14 University Clinic of Navarra, Pamplona, Spain
15 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Barcelona, Spain
16 Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL) and Biomedical Research Institute (IDIBGI), Barcelona-Girona, Spain
17 Hospital Vall d’Hebron and Universitat Autonoma de Barcelona, Barcelona, Spain
18 Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain
19 Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
20 MRC Cancer Unit, Hutchison-MRC Research Centre, Cambridge, United Kingdom
21 University of Manchester, Manchester, United Kingdom
22 Manchester Centre for Genomic Medicine, Manchester, United Kingdom
23 St Georges NHS Foundation Trust, London, United Kingdom
24 Biocant- Transfer Technology Association, Cantanhede, Portugal
25 Biocruces Health Research Institute, Barakaldo, Spain
26 University of Cambridge, Cambridge, United Kingdom
27 Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
28 TU Dresden, Medical Faculty CGC, Dresden, Germany
29 Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
30 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
31 Genomed Diagnósticos de Medicina Molecular, S.A., Lisbon, Portugal
32 Institute of Oncology Ljubljana, Ljubljana, Slovenia
33 Elche University Hospital, Elche, Spain
34 Karolinska Institutet, Stockholm, Sweden
35 Institut de Pathologie et de Génétique, Gosselies, Belgium
Topic
Digestive Oncology, Histopathology
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]